Skip to content

Adolescents with HIV do better in more prosperous African countries, even with treatment

Presenter Amy Slogrove with IAS President Linda-Gail Bekker at IAS 2017. Photo by Marcus Rose/IAS

France’s next PrEP study aims to assess the wider impact of PrEP on the HIV epidemic

The team at ANRS Prévenir. http://prevenir.anrs.fr

Dutch study finds out whether gay men prefer daily or on-demand PrEP

Hanne Zimmermann presenting at IAS 2017. Image credit: Ejay de Wit (@ejaydewit)

Long-acting cabotegravir injection shows promise for HIV prevention

Raphael Landovitz at IAS 2017. Photo by Liz Highleyman, hivandhepatitis.com

Doravirine combination pill looks good for initial HIV treatment

Kathleen Squires at IAS 2017. Photo by Liz Highleyman, hivandhepatitis.com

Acute kidney injury ‘uncommon’ but unpredictable on tenofovir and ritonavir

Acute kidney injury ‘uncommon’ but unpredictable on tenofovir and ritonavir

Countries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows

Dzintars Gotham presenting at IAS 2017. Image credit: Enzo Poultreniez / http://aides.org

Medical male circumcision for HIV has benefits for women too

Carlos Toledo presenting at IAS 2017. Photo by Roger Pebody, aidsmap.com

Demonstration projects explore the feasibility of PrEP for adolescents and young women in South Africa

Katherine Gill presenting at IAS 2017. Photo by Roger Pebody, aidsmap.com